You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

Article info

Article menu

This article has a correction. Please see:

XML
Oncolytic and local immunotherapy
Original research
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

Authors

  • Firas Hamdan Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, FinlandTRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, FinlandDrug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Erkko Ylösmäki Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, FinlandTRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, FinlandDrug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Jacopo Chiaro Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, FinlandTRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, FinlandDrug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Yvonne Giannoula Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, Finland PubMed articlesGoogle scholar articles
  • Maeve Long Translational Stem Cell Biology & Metabolism Program, Research Programs Unit, Department of Anatomy, Faculty of Medicine, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Manlio Fusciello Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, FinlandTRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, FinlandDrug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Sara Feola Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, FinlandTRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, FinlandDrug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Beatriz Martins Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, FinlandTRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, FinlandDrug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Michaela Feodoroff Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, FinlandTRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, FinlandDrug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Gabriella Antignani Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, FinlandTRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, FinlandDrug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Salvatore Russo Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, FinlandTRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, FinlandDrug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Otto Kari Drug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Moon Hee Lee TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, FinlandHematology Research Unit Helsinki, University of Helsinki, Helsinki, Uusimaa, Finland PubMed articlesGoogle scholar articles
  • Petrus Järvinen Abdominal Center, Urology, Helsinki University Central Hospital, Helsinki, Uusimaa, Finland PubMed articlesGoogle scholar articles
  • Harry Nisen Abdominal Center, Urology, Helsinki University Central Hospital, Helsinki, Uusimaa, Finland PubMed articlesGoogle scholar articles
  • Anna Kreutzman Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, FinlandTRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, FinlandDrug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Jeanette Leusen Center for Translational Immunology, UMC Utrecht, Utrecht, Netherlands PubMed articlesGoogle scholar articles
  • Satu Mustjoki TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, FinlandHematology Research Unit Helsinki, University of Helsinki, Helsinki, Uusimaa, FinlandiCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, FinlandDepartment of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Thomas G McWilliams Translational Stem Cell Biology & Metabolism Program, Research Programs Unit, Department of Anatomy, Faculty of Medicine, Biomedicum Helsinki, University of Helsinki, Helsinki, FinlandDepartment of Anatomy, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Mikaela Grönholm Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, FinlandTRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, FinlandDrug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, FinlandiCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Vincenzo Cerullo Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Uusimaa, FinlandTRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Uusimaa, FinlandDrug Delivery, Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, FinlandiCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, FinlandDepartment of Molecular Medicine and Medical Biotechnology and CEINGE, Naples University 24 Federico II, 80131, Naples, Italy PubMed articlesGoogle scholar articles

Citation

Hamdan F, Ylösmäki E, Chiaro J, et al
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
Journal for ImmunoTherapy of Cancer 2021;9:e003000. doi: 10.1136/jitc-2021-003000
Online issue publication 
November 02, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.